About Eagle Pharmaceuticals (NASDAQ:EGRX)
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300
Debt
Debt-to-Equity Ratio0.24%
Current Ratio3.99%
Quick Ratio3.88%
Price-To-Earnings
Trailing P/E Ratio15.03
Forward P/E Ratio22.59
P/E GrowthN/A
Sales & Book Value
Annual Sales$236.71 million
Price / Sales3.46
Cash Flow$3.8654 per share
Price / Cash14.26
Book Value$12.01 per share
Price / Book4.59
Profitability
EPS (Most Recent Fiscal Year)$3.37
Net Income$51.94 million
Net Margins21.94%
Return on Equity34.16%
Return on Assets23.74%
Miscellaneous
Employees108
Outstanding Shares14,860,000
Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions
What is Eagle Pharmaceuticals' stock symbol?
Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."
How will Eagle Pharmaceuticals' stock buyback program work?
Eagle Pharmaceuticals declared that its board has approved a share buyback plan on Thursday, August 10th 2017, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 13.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.
How were Eagle Pharmaceuticals' earnings last quarter?
Eagle Pharmaceuticals (NASDAQ:EGRX) released its quarterly earnings results on Monday, February, 26th. The specialty pharmaceutical company reported $0.84 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.00 by $0.16. The specialty pharmaceutical company earned $46.80 million during the quarter, compared to analyst estimates of $53.65 million. Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. Eagle Pharmaceuticals's quarterly revenue was down 42.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.52 EPS. View Eagle Pharmaceuticals' Earnings History.
What price target have analysts set for EGRX?
3 Wall Street analysts have issued 1-year price targets for Eagle Pharmaceuticals' shares. Their predictions range from $40.00 to $79.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $63.3333 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.
What are Wall Street analysts saying about Eagle Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (3/1/2018)
- 2. Mizuho analysts commented, "We attribute the miss to lower revenues and higher COGS. Eagle previously announced that it plans to initiate another pivotal trial of Ryanodex in exertional heat stroke (EHS) at the Hajj pilgrimage in August. We view this initiative as largely unproductive because identifying appropriate patients and trial execution could prove challenging yet again. However, enrollment in the fulvestrant trial was faster than expected (data could be a catalyst in the coming months) and Eagle has advanced one of its ANDA filings, which are slight positives to the story. In the past week we saw announcements that two senior executives (Chief Scientific Officer and General Counsel) have left Eagle, which we believe bodes poorly for the future outlook of the company. We reiterate our Underperform rating on the stock and will update thoughts after the call. We summarize 4Q:17 performance below." (2/26/2018)
Who are some of Eagle Pharmaceuticals' key competitors?
Some companies that are related to Eagle Pharmaceuticals include Tesaro (TSRO), Array BioPharma (ARRY), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Ironwood Pharmaceuticals (IRWD), Acadia Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Horizon Pharma (HZNP) and Global Blood Therapeutics (GBT).
Who are Eagle Pharmaceuticals' key executives?
Eagle Pharmaceuticals' management team includes the folowing people:
- Mr. Scott L. Tarriff, Chief Exec. Officer and Director (Age 58)
- Mr. David M. Pernock, Pres and Chief Commercial Officer (Age 65)
- Dr. Adrian Hepner M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 57)
- Mr. Pete A. Meyers, Chief Financial Officer and Principal Accounting Officer (Age 48)
- Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)
Has Eagle Pharmaceuticals been receiving favorable news coverage?
News coverage about EGRX stock has trended somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 47.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Eagle Pharmaceuticals?
Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eagle Pharmaceuticals' stock price today?
One share of EGRX stock can currently be purchased for approximately $55.12.
How big of a company is Eagle Pharmaceuticals?
Eagle Pharmaceuticals has a market capitalization of $817.56 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.
How can I contact Eagle Pharmaceuticals?
Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]
MarketBeat Community Rating for Eagle Pharmaceuticals (EGRX)
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Eagle Pharmaceuticals (NASDAQ:EGRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Eagle Pharmaceuticals in the last 12 months. Their average twelve-month price target is $63.3333, suggesting that the stock has a possible upside of 14.90%. The high price target for EGRX is $79.00 and the low price target for EGRX is $40.00. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.33 | 2.33 | 2.33 | 2.50 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $63.3333 | $63.3333 | $62.3333 | $72.50 |
| Price Target Upside: | 14.90% upside | 20.91% upside | 12.68% upside | 34.06% upside |
Eagle Pharmaceuticals (NASDAQ:EGRX) Consensus Price Target History
Eagle Pharmaceuticals (NASDAQ:EGRX) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Eagle Pharmaceuticals (NASDAQ:EGRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.50%
Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | Sander A Flaum | Director | Sell | 2,340 | $53.94 | $126,219.60 | |  |
| 8/16/2017 | Pete A Meyers | CFO | Buy | 350 | $55.45 | $19,407.50 | 700 | |
| 8/9/2017 | Douglas L Braunstein | Director | Buy | 20,400 | $49.07 | $1,001,028.00 | | |
| 6/12/2017 | Pete A Meyers | CFO | Buy | 350 | $71.49 | $25,021.50 | 350 | |
| 5/19/2017 | David Pernock | Insider | Buy | 255 | $79.69 | $20,320.95 | 966 | |
| 5/16/2017 | David Pernock | Insider | Buy | 200 | $82.24 | $16,448.00 | 711 | |
| 4/25/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 54,180 | $88.38 | $4,788,428.40 | | |
| 4/3/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 91,332 | $83.09 | $7,588,775.88 | | |
| 3/29/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 106,468 | $83.01 | $8,837,908.68 | | |
| 3/28/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 6,182 | $83.02 | $513,229.64 | | |
| 3/27/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 39,431 | $83.00 | $3,272,773.00 | | |
| 3/23/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 1,200 | $83.05 | $99,660.00 | | |
| 3/23/2017 | Steven L Krill | EVP | Sell | 14,125 | $81.07 | $1,145,113.75 | 5,023 | |
| 3/22/2017 | Richard A Edlin | Director | Buy | 6,000 | $79.44 | $476,640.00 | 29,400 | |
| 3/21/2017 | David Pernock | Insider | Buy | 61 | $83.98 | $5,122.78 | 511 | |
| 3/20/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 100,000 | $82.06 | $8,206,000.00 | | |
| 3/9/2017 | David Pernock | Insider | Buy | 450 | $77.84 | $35,028.00 | 450 | |
| 1/4/2017 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 65,114 | $85.16 | $5,545,108.24 | | |
| 12/13/2016 | Steven B Ratoff | Director | Sell | 10,000 | $75.01 | $750,100.00 | 23,324 | |
| 11/28/2016 | Sander A Flaum | Director | Sell | 5,000 | $78.66 | $393,300.00 | 11,374 | |
| 11/11/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 34,486 | $85.15 | $2,936,482.90 | | |
| 11/9/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 153,830 | $79.29 | $12,197,180.70 | | |
| 11/7/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 5,030 | $75.39 | $379,211.70 | | |
| 11/4/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 245,770 | $71.02 | $17,454,585.40 | | |
| 9/30/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 22,100 | $70.06 | $1,548,326.00 | | |
| 9/29/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 77,900 | $70.04 | $5,456,116.00 | | |
| 9/21/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 99,795 | $66.17 | $6,603,435.15 | | |
| 9/8/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 70,925 | $62.50 | $4,432,812.50 | | |
| 8/24/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 28,870 | $63.00 | $1,818,810.00 | | |
| 8/17/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 99,795 | $61.36 | $6,123,421.20 | | |
| 8/16/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 60,150 | $61.67 | $3,709,450.50 | | |
| 8/15/2016 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 24,949 | $60.77 | $1,516,150.73 | | |
| 5/13/2016 | Proquest Management Llc | Major Shareholder | Sell | 17,980 | $40.72 | $732,145.60 | | |
| 4/1/2016 | Scott Tarriff | CEO | Sell | 30,765 | $40.63 | $1,249,981.95 | 1,369,946 | |
| 3/15/2016 | Michael Graves | Director | Buy | 1,000 | $56.73 | $56,730.00 | 1,000 | |
| 2/1/2016 | Scott Tarriff | CEO | Sell | 18,360 | $68.08 | $1,249,948.80 | 1,420,491 | |
| 12/22/2015 | Sander A. Flaum | Director | Sell | 13,025 | $54.81 | $713,900.25 | 16,374 | |
| 12/1/2015 | Scott Tarriff | CEO | Sell | 14,050 | $88.93 | $1,249,466.50 | 1,453,400 | |
| 11/2/2015 | Scott Tarriff | CEO | Sell | 19,339 | $64.63 | $1,249,879.57 | 1,467,450 | |
| 10/1/2015 | Scott Tarriff | CEO | Sell | 17,878 | $69.92 | $1,250,029.76 | 1,486,789 | |
| 9/1/2015 | Scott Tarriff | CEO | Sell | 16,245 | $76.95 | $1,250,052.75 | 1,504,667 | |
| 7/1/2015 | Scott Tarriff | CEO | Sell | 135,710 | $46.34 | $6,288,801.40 | | |
| 6/16/2015 | Steven L Krill | Insider | Sell | 9,980 | $81.60 | $814,368.00 | | |
| 2/18/2014 | Jay Moorin | Director | Buy | 333,333 | $15.00 | $4,999,995.00 | | |
(Data available from 1/1/2013 forward)
Eagle Pharmaceuticals (NASDAQ EGRX) News Headlines
| Source: |
|
Eagle Pharmaceuticals (NASDAQ:EGRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Eagle Pharmaceuticals (NASDAQ:EGRX) Income Statement, Balance Sheet and Cash Flow Statement
Eagle Pharmaceuticals (NASDAQ EGRX) Stock Chart for Thursday, April, 26, 2018
Loading chart…
